# 1 Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta and Delta 2 plus variants

Thandeka Moyo-Gwete<sup>1,2</sup>, Mashudu Madzivhandila<sup>1,2</sup>, Nonhlanhla N Mkhize<sup>1,2</sup>,

3

4

9

Prudence Kgagudi<sup>1,2</sup>, Frances Ayres<sup>1,2</sup>, Bronwen E Lambson<sup>1,2</sup>, Nelia P
Manamela<sup>1,2</sup>, Simone I Richardson<sup>1,2</sup>, Zanele Makhado<sup>1,2</sup>, Mieke A van der Mescht<sup>3</sup>,
Zelda de Beer<sup>4</sup>, Talita Roma de Villiers<sup>4</sup>, Wendy A Burgers<sup>5,6</sup>, Ntobeko A B Ntusi<sup>6,7,8</sup>,
Theresa Rossouw<sup>3</sup>, Veronica Ueckermann<sup>9</sup>, Michael T Boswell<sup>9</sup>,

Penny L Moore<sup>1,2,5,10</sup>\*

<sup>1</sup>National Institute for Communicable Diseases of the National Health Laboratory 10 Service, Johannesburg, South Africa. <sup>2</sup>MRC Antibody Immunity Research Unit, 11 12 School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg. South Africa. <sup>3</sup>Department of Immunology, Faculty of Health 13 Sciences, University of Pretoria, Pretoria, South Africa. <sup>4</sup>Tshwane District Hospital, 14 Pretoria, South Africa. <sup>5</sup>Institute of Infectious Disease and Molecular Medicine, 15 Division of Medical Virology, Department of Pathology, University of Cape Town, 16 Cape Town, South Africa. <sup>6</sup>Wellcome Centre for Infectious Diseases Research in 17 Africa, University of Cape Town, Cape Town, South Africa. <sup>7</sup>Division of Cardiology, 18 Department of Medicine, University of Cape Town and Groote Schuur Hospital, 19 Cape Town, South Africa. <sup>8</sup>Cape Heart Institute, Faculty of Health Sciences, 20 University of Cape Town, Cape Town, South Africa. <sup>9</sup>Division for Infectious 21 Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and 22 University of Pretoria, Pretoria, South Africa. <sup>10</sup>Centre for the AIDS Programme of 23 Research in South Africa (CAPRISA), Durban, South Africa. 24

- 25 \*Corresponding author
- 26
- 27
- 28

#### 29 Abstract

#### 30

31 As SARS-CoV-2 continues to evolve, several variants of concern (VOCs) have 32 arisen which are defined by multiple mutations in their spike proteins. These VOCs 33 have shown variable escape from antibody responses, and have been shown to 34 trigger qualitatively different antibody responses during infection. By studying plasma 35 from individuals infected with either the original D614G, Beta or Delta variants, we 36 show that the Beta and Delta variants elicit antibody responses that are overall more 37 cross-reactive than those triggered by D614G. Patterns of cross-reactivity varied, 38 and the Beta and Delta variants did not elicit cross-reactive responses to each other. 39 However, Beta-elicited plasma was highly cross-reactive against Delta plus (Delta+) 40 which differs from Delta by a single K417N mutation in the receptor binding domain, 41 suggesting the plasma response targets the N417 residue. To probe this further, we 42 isolated monoclonal antibodies from a Beta-infected individual with plasma 43 responses against Beta, Delta+ and Omicron, which all possess the N417 residue. 44 We isolated a N417-dependent antibody, 084-7D, which showed similar 45 neutralization breadth to the plasma. The 084-7D mAb utilized the IGHV3-23\*01 46 germline gene and had similar somatic hypermutations compared to previously 47 described public antibodies which target the 417 residue. Thus, we have identified a novel antibody which targets a shared epitope found on three distinct VOCs, 48 49 enabling their cross-neutralization. Understanding antibodies targetting escape 50 mutations such as K417N, which repeatedly emerge through convergent evolution in 51 SARS-CoV-2 variants, may aid in the development of next-generation antibody 52 therapeutics and vaccines.

53

- 55
- 56

#### 57 Importance

#### 

The evolution of SARS-CoV-2 has resulted in variants of concern (VOCs) with distinct spike mutations conferring varying immune escape profiles. These variable mutations also influence the cross-reactivity of the antibody response mounted by individuals infected with each of these variants. This study sought to understand the antibody responses elicited by different SARS-CoV-2 variants, and to define shared epitopes. We show that Beta and Delta infection resulted in antibody responses that were more cross-reactive compared to the original D614G variant, but each with differing patterns of cross-reactivity. We further isolated an antibody from Beta infection, which targeted the N417 site, enabling cross-neutralization of Beta, Delta+ and Omicron, all of which possess this residue. The discovery of antibodies which target escape mutations common to multiple variants highlights conserved epitopes to target in future vaccines and therapeutics.

#### 88 Introduction

89

90 Since the emergence of SARS-CoV-2 in 2019, several variants of concern (VOCs) 91 and interest (VOIs) have emerged. Many of these variants contain mutations in the 92 spike protein that confer escape from neutralizing antibodies (1). The first 93 neutralization-resistant VOC identified, Beta, contained receptor binding domain 94 (RBD) mutations at positions K417N and E484K, which confer escape from Class I and Class II neutralization antibodies, respectively (2, 3). These mutations have 95 96 since been observed in multiple variants. One such example is the charge-altering 97 E484K/Q/A mutation, which occurs in several variants including Gamma, the Delta 98 lineage, C.1.2 and A.VOI.V2 (1, 4-6). The E484K mutation is also present in Omicron 99 (first identified in South Africa) which is the most neutralization-resistant variant 100 identified to date, evading both convalescent and vaccine-elicited antibody 101 responses (5, 7-9).

102

103 Similarly, the K417N mutation found in the Beta variant has also emerged in other 104 VOC/VOIs throughout the world. This mutation results in a change from a positively 105 charged residue (lysine, K) to an uncharged asparagine (N) residue - a difference 106 large enough to prevent binding of antibodies dependent on this epitope (3). This 107 substitution results in escape from Class I neutralizing antibodies such as the 108 therapeutic monoclonal antibody (mAb), etesevimab (10, 11). The K417N mutation 109 also occurs in a sublineage of Delta, called Delta plus (Delta+), and in the Omicron 110 variant (BA.1) and its sub-lineages (BA.2, BA.3, BA.4 and BA5) (12), indicating that 111 an antibody that targets this site may cross-neutralize these variants.

112

113 The high levels of convergent evolution observed globally between variants indicates 114 that at a population level, neutralizing antibodies target similar regions of the SARS-115 CoV-2 spike protein. This is supported by numerous monoclonal antibody (mAb) 116 isolation studies which identified the RBD as the major target of the neutralizing 117 antibody response, regardless of the infecting variant or type of vaccination (13-17). 118 However, there is substantial evidence that the antibody response towards the RBD 119 differs in fine specificity depending on which variant triggered the infection. The 120 original (D614G) variant triggers antibodies with very low levels of cross-reactivity to 121 the Beta variant (3). Responses elicited by the Beta variant however, exhibit higher

122 levels of cross-reactivity towards the D614G and the Gamma variant (18) but not 123 against the Delta variant (19, 20). Similarly, Delta-elicited responses have low cross-124 reactivity towards the Beta variant (15, 21). It has therefore been suggested that the 125 Beta and Delta variants took divergent evolutionary pathways towards distinct 126 groupings or "serotypes", with the D614G original variant being serologically closer 127 to Delta than Beta (19). The Omicron variant elicits predominantly Omicron-specific 128 antibodies, with poor cross-reactivity against Delta and C.1.2 and D614G, and a 129 dramatic 31-fold reduction in activity against Beta (22). Defining the fine specificity of 130 neutralizing antibodies elicited by the different variants is therefore important to 131 determine whether there are common responses targeting divergent variants.

132

133 In this study, we compared the cross-reactivity of plasma responses during three 134 separate SARS-CoV-2 waves in South Africa. Each epidemic wave in South Africa 135 was dominated by a distinct variant; first D614G, then Beta, followed by Delta. We 136 first assessed the neutralizing antibody responses elicited by each of the three 137 variants against a panel of circulating VOCs and SARS-CoV-1. We show that Beta 138 and Delta infection elicited more cross-reactive responses than the D614G variant, 139 though the patterns of cross-reactivity were different. Furthermore, Beta-elicited 140 plasma potently neutralized the Delta+ variant compared to the Delta variant, 141 suggesting these cross-reactive antibodies may target the N417 residue, as this is 142 the only spike mutation that differentiates these two variants. To confirm this, we 143 isolated and characterized a mAb from a Beta-infected individual who showed 144 plasma neutralization of Beta, Delta+ and Omicron. Epitope mapping revealed that 145 this mAb, 084-7D, recapitulated much of the plasma breadth and was heavily 146 dependent on a shared N417 epitope. The discovery of cross-reactive mAbs may aid 147 in the development of universal SARS-CoV-2 therapeutic antibodies and inform the 148 design of booster vaccines.

- 149
- 150
- 151
- 152
- 153

#### 154 **Results**

155

### Neutralizing responses triggered by variants of concern possess differential patterns of cross-reactivity

158

159 We first compared antibody responses in unvaccinated individuals infected by VOCs 160 circulating in three distinct SARS-CoV-2 epidemiological waves in South Africa from 161 May 2020 to July 2021. In each wave, sampling occurred at the time when each 162 respective variant was responsible for at least 90% of infections, and sequencing in 163 a subset of matched nasal swabs confirmed the infecting variant. We investigated 164 how well plasma elicited by D614G, Beta and Delta variants neutralized multiple 165 VOCs, as well as SARS-CoV-1 (Figure 1A and 1B). D614G-elicited plasma 166 triggered robust neutralization of the matched D614G spike (autologous 167 neutralization), but showed very low levels of cross-reactivity, with a 12-15-fold 168 decrease in neutralization towards all SARS-CoV-2 VOCs tested and to SARS-CoV-169 1 (Figure 1A). In contrast, as we previously reported, plasma from Beta infections 170 was highly cross-reactive against the D614G variant (2.9 fold reduction) (18) but 171 showed less cross-reactivity against other VOCs, with reductions against Delta, 172 Omicron and SARS-CoV-1 of 11.3-fold, 9.4-fold and 9.3-fold, respectively (Figure 173 **1A**). We also tested plasma from Delta-infected individuals and found that although 174 autologous titers against the matched spike were very high, there was a 15-41-fold 175 drop in neutralization potency across VOC/VOIs and SARS-CoV-1. The higher level 176 of cross-reactivity for the D614G variant (15-fold drop in potency, compared to Beta 177 (35-fold drop) in Delta-elicited plasma is consistent with what others have reported 178 (19, 21).

179

180 To get a measure of the degree and patterns of cross-reactivity for each variant, we 181 compared the geometric mean titers (GMTs) of the plasma response elicited by the 182 three variants towards various VOCs and SARS-CoV-1 using a spider plot (Figure 183 **1B**). Each variant triggered the highest responses against their corresponding 184 autologous virus as expected. Furthermore, the extent of autologous neutralization 185 varied, with Delta triggering particularly high autologous responses (GMT: 2,819), 186 compared to Beta (GMT:1,282) or D614G (GMT:621), likely a consequence of the 187 high viral loads in Delta infections (23). We therefore calculated a single measure of

breadth, by assessing the cumulative area under the curve (AUC) value for all variants, normalized relative to the GMT of the autologous virus to account for differential potency of responses (**Figure 1B**). Beta- and Delta-elicited responses were both approximately 2-fold higher (AUC: 114 and 103) than D614G (AUC: 52) (**Figure 1B**), indicating that the neutralizing responses triggered by these two variants were more cross-reactive than those elicited by the early circulating SARS-CoV-2 variant.

195

196 Although other sites, such as the RBD Class III antibody binding site, have 197 previously been implicated as targets of the Beta-elicited responses (14) the N417K 198 mutation in the Beta RBD has also been shown to be a dominant target of Beta-199 elicited plasma (24, 25). To assess whether antibodies to this site accounted for the 200 breadth in Beta-infected individuals, we tested Beta plasma against the Delta+ 201 variant, which differs from Delta only at K417N, the same mutation that is also found 202 in Beta (Figure 1C). This mutation is the only shared mutation in the RBD regions of 203 the Beta and Delta+ lineages. Compared to the Beta response towards Delta which 204 showed a significant drop in potency (6.1-fold), there was only a 2.5-fold drop in 205 potency against Delta+ (Figure 1C). These data confirm the importance of the N417 206 residue as a target of Beta-elicited cross-reactive neutralizing antibody responses.

207

## Isolation and characterization of a SARS-CoV-2 cross-reactive, neutralizing monoclonal antibody from a Beta-infected individual

210

211 To assess whether the N417 residue was a target of Beta-elicited mAb responses, 212 we sought to isolate mAbs from a Beta-infected individual who developed potent 213 responses towards the Beta variant and was cross-reactive towards other VOCs. We 214 previously recruited participant SA-01-0084 (084) into our cohort of hospitalized 215 patients infected with the Beta variant (18). This participant was female, below the 216 age of 60, HIV-uninfected, and had their blood drawn two days after a positive 217 SARS-CoV-2 RT-PCR test (Figure 2A). Plasma from donor 084 potently neutralized 218 Beta ( $ID_{50} = 7,613$ ) and Delta+ ( $ID_{50} = 12,083$ ) pseudoviruses (**Figure 2B**). The 084 219 plasma also potently neutralized Omicron ( $ID_{50} = 9,882$ ). However, it did not 220 neutralize the D614G, Delta or SARS-CoV-1 pseudovirus and had weak 221 neutralization against Gamma and A.VOI.V2 (ID<sub>50</sub><120) (Figure 2B). The high cross-

reactivity of the plasma towards Delta+ was similar to what we observed with other
 Beta-elicited plasma (Figure 1C).

224 We performed single cell sorting of the participant's peripheral blood mononuclear 225 cells (PBMCs). Using Beta and D614G spike proteins as cell sorting baits, we sorted 226 a total of 68 cells, with approximately 58 of the cells being Beta-specific and the rest 227 of the cells being double-positive (Figure 2C). We identified an IgG1 mAb, 084-7D, 228 which bound to the Beta spike antigen (Figure 2). We tested the functionality of mAb 229 084-7D by first examining its neutralizing activity against the same VOCs we had 230 tested the plasma against (Figure 2D). The 084-7D mAb showed a very similar 231 cross-reactivity pattern to the matched sera, exhibiting potent neutralization of Beta 232  $(IC_{50} = 0.10 \ \mu g/ml)$  and Delta+  $(IC_{50} = 0.01 \ \mu g/ml)$ , though slightly lower activity 233 against Omicron (IC<sub>50</sub> = 3.31  $\mu$ g/ml) than was observed in the plasma. The mAb did 234 not neutralize SARS-CoV-1 or the other VOC/VOIs tested (Figure 2D). These data 235 indicate that this mAb recapitulated the dominant response in the plasma, though it 236 did not entirely account for Omicron plasma neutralization.

237

### 084-7D mAb epitope mapping reveals spike target that is highly dependent on the N417 residue

240

241 To map the spike target of the mAb, we conducted binding experiments using a 242 SARS-CoV-2-specific enzyme linked immunosorbent assay (ELISA). The antibody 243 bound the full Beta spike but not the D614G spike as expected based on the 244 neutralization assay results (Figure 2E). No binding was observed for either the Beta or D614G N-terminal domnain (NTD) proteins, but strong binding was detected 245 246 towards the Beta RBD (Fig. 2E). We expressed single mutants representing the 247 three RBD mutations found in the Beta variant - K417N, E484K and N501Y - in an 248 SBD (subdomain 1) backbone and tested whether the antibody was able to 249 recognize any of the Beta mutations. The 084-7D mAb bound to the K417N mutant 250 but did not bind to the D614G SBD or E484K and N501Y single mutants (Figure 251 **2E**). Overall, these data suggest that the 084-7D mAb is dependent on the N417 252 residue present in the Beta RBD.

253

254 mAb 084-7D exhibits Fc effector functionality, particularly against the Beta 255 variant

256

257 We have previously shown that, in addition to neutralization, the Beta variant triggers 258 cross-reactive Fc functionality compared to D614G (26). We therefore analyzed the 259 ability of the 084-7D mAb to mediate antibody-dependent cellular phagocytosis 260 (ADCP) and measured the ability of mAb 084-7D to cross-link CD16 and SARS-261 CoV-2 spike proteins expressed on cells as a proxy for antibody-dependent cellular 262 cytotoxicity (ADCC). Both of these effector functions have been shown to contribute 263 to decreased severity of SARS-CoV-2 infection and are required for optimal 264 protection from infection by monoclonal antibodies (27). We compared mAb 084-7D 265 to control mAbs, P2B-2F6 and CR3022. The 084-7D mAb mediated strong 266 phagocytic activity against the Beta variant (AUC: 1,513) but up to 3-fold weaker 267 activity against the D614G and Omicron variants (AUC: 209 and 468 respectively) 268 (Figure 3A). In comparison, P2B-2F6, which targets a Class II RBD epitope, 269 mediated strong ADCP against D614G, but much lower levels against Beta and no 270 activity against Omicron, as expected. The CR3022 mAb showed cross-reactive 271 ADCP to all three variants, as previously reported (22). The 084-7D mAb exhibited 272 ADCC activity against the Beta (AUC: 25,937) and Omicron (AUC: 15,551) variants 273 while no activity was detected for the D614G variant (Figure 3B). The P2B-2F6 mAb 274 displayed strong ADCC activity against the D614G variant (AUC:113,631) as 275 expected but no activity towards Beta and Omicron. CR3022 had similar activity 276 across the three variants. Overall, the 084-7D mAb mediated Fc effector functionality 277 with similar patterns of cross-reactivity to that observed in neutralization, exhibiting 278 ADCP and ADCC activity against the Beta variant but reduced activity against 279 Omicron.

280

## 084-7D is related to a broad and potent N417-dependent antibody isolated from early pandemic infection

283

We next investigated the genetics of mAb 084-7D to determine whether it could be classified amongst other RBD-targeting mAbs based on germline gene usage and epitope targeting (**Figure 4**). The 084-7D antibody was isolated as an IgG1, IgA1 and IgM but was cloned and tested as an IgG1 for this study (**Figure 1A**). The mAb uses the 3-23\*01 variable heavy (VH) chain gene, exhibiting 5.9% somatic hypermutation in the variable gene region, despite being isolated early in infection

(Figure 4A). The 1-5\*03 variable kappa (VK) chain gene is used by this mAb, and we observed less somatic hypermutation in the VK gene (2.9%) compared to the heavy chain. We compared the 084-7D mAb to a previously reported SARS-CoV-2 RBD-specific antibody, CAB-A17, that utilizes the VH3-53\*01 germline gene, which is similar to VH3-23\*01 with 91% identity. The CAB-A17 lineage developed VOC cross-neutralization through interactions with the N417 residue, suggesting similar epitope targeting compared to mAb 084-7D (28).

297

Sheward *et al.* identified four key mutations in the heavy chain of the broad mAb, CAB-A17, which likely contributed to the increased breadth observed: G26E, T28I, S53P and Y58F (Kabat numbering). Alignment of the VH3-23\*01 (used by 084-7D), VH3-53\*01 (used by CAB-A17), CAB-A17 and 084-7D heavy chain sequences (truncated at the CDRH3 region) showed that the 084-7D mAb had mutations at two of the same key residues, T28S and S53G, although the amino acid changes differed from the CAB-A17 mAb mutations (**Figure 4A**).

305

Furthermore, the light chain of Class I K417-targeting antibodies has been shown to play a role in epitope interactions through the CDRL1 <sup>28</sup>VSSS<sup>31</sup>-motif (Kabat numbering) (13, 28). We noted that the 084-7D mAb possessed a germline encoded ISS-motif, which is similar to the CAB-A17 mAb which also had a deletion in this region, resulting in an LST-motif (**Figure 4B**). Altogether, these data show that the 084-7D mAb is similar to a highly broad and potent mAb which targets a similar epitope.

- 313
  314
  315
  316
  317
  318
  319
  320
  321
  322
- 323
- 324
- 325

- 326 327
- 328
- 329
- 020
- 330 331

#### 332 Discussion

333

334 In this study, we investigated the cross-reactive potential of plasma elicited by three 335 different variants that circulated in South Africa during three sequential waves of 336 infection - the D614G, Beta and Delta variants. Antibodies generated by the Beta 337 and Delta variants exhibited higher levels of cross-reactivity as compared to those 338 triggered by the original D614G variant confirming that SARS-CoV-2 variants elicit 339 varying antibody responses, potentially targeting different epitopes on the spike 340 protein. Secondly, we used a mAb isolated from a Beta-infected donor to define a 341 N417-dependent neutralizing antibody epitope shared between the Beta, Delta+ and 342 Omicron variants. This mAb exhibited similar genetic features to a potent and broad 343 N417-dependent antibody, suggesting that this site may be commonly targeted by 344 SARS-CoV-2 cross-reactive mAbs.

345

346 The K417N mutation has been implicated in immune escape from Delta-elicited 347 plasma and this may explain the lack of cross-reactivity between Beta and Delta 348 antibody responses (15). In line with this, we found that although Delta+ and Delta 349 spike sequences only differ by one amino acid (N417 in Delta+ and K417 in Delta), 350 antibodies elicited by the Beta variant showed cross-reactivity against the Delta+ VOI 351 but very little cross-reactivity towards the Delta VOC. Our findings suggest that the 352 Beta-elicited plasma responses we tested were preferentially targeting an epitope 353 that was dependent on the N417 residue that is found in the Beta, Delta+ and 354 Omicron VOCs. Our data confirms findings by other groups who have shown that the 355 N417-directed response accounts for a large proportion of the Beta-elicited response 356 in some individuals (24, 25).

357

Here, we isolated an N417-dependent mAb from a Beta-infected individual which neutralized and performed Fc effector function against the Beta, Delta+ and Omicron VOCs. The 084-7D mAb utilizes the VH3-23\*01 germline gene, and members of this

361 class of mAbs have previously been shown to target the RBD (29, 30). VH3 gene 362 families are well-documented in targeting this site, including Class I antibodies which 363 bind to the K417-residue (13, 29). The VH3 group of antibodies have been classed 364 as public antibodies suggesting that they can be easily elicited in SARS-CoV-2 365 infection and vaccination (29, 31, 32). Similar to the 084-7D mAb, low levels of 366 somatic hypermutation are needed for most VH3 SARS-CoV-2 antibodies to 367 neutralize their target, suggesting that germline-encoded sequences, such as in the 368 CDRH2 and CDRL2, play a sufficient role in epitope recognition (13). These 369 characteristics of mAb 084-7D make it attractive to pursue as a vaccine target.

370

371 Although many aspects of neutralization are germline encoded, increased somatic 372 hypermutation enhances the maturation of breadth to SARS-CoV-2 VOCs (33), as 373 for other pathogens (34, 35). As mAb 084-7D was isolated from blood drawn only 374 two days after testing positive for SARS-CoV-2, this antibody was isolated too early 375 to have accumulated substantial somatic hypermutation. Plasma from donor 084 376 collected at the same timepoint was highly potent against Omicron, but the 084-7D 377 mAb displayed less potency against this variant. This suggests that there may be 378 other antibodies in the plasma which are cross-reactive against Omicron.

379

380 The lack of neutralization and Fc effector of mAb 084-7D against Omicron compared 381 to the Beta and Delta+ variants may be impacted by the fact that the Beta and 382 Delta+ variants each possess three mutations in their RBD regions, including the 383 K417N mutations, whilst Omicron possesses at least 17 mutations in that region (5). 384 The numerous mutations clustered around the Y501 residue in Omicron may have 385 an impact on mAb 084-7D interactions as this region has been shown to be 386 important for Class I antibody CDRL1 interactions (29). Although our data focused 387 on the interaction between this mAb and the N417 residue, the complete epitope-388 paratope interaction must be investigated through the determination of a high-389 resolution structure. This will delineate the role of other residues in creating the full 390 epitope of this mAb to decipher its relatively lower levels of potency towards 391 Omicron.

392

A recently described mAb, CAB-A17, shares similar genetic and epitope-dependent
 traits to mAb 084-7D (28). However, mAb CAB-A17 has substantially more breadth

395 across VOCs and is also more potent against Omicron than the 084-7D mAb (28). 396 Exploring the differences between the two mAbs may suggest a mechanism required 397 to achieve high levels of breadth and potency in this class of antibody. The CAB-A17 398 mAb contains key mutations that resulted in increased breadth towards the Omicron 399 variant - G26E, T28I, S53P and Y58F. The 084-7D mAb contains 2/4 of these 400 mutations although the residue changes differ - T28S and S53G. The changes in 401 mAb CAB-A17 at these sites are much more substantial, especially the serine to 402 proline change at position 53 that may alter the conformation of that region and 403 therefore affect epitope binding. These differences may contribute to the disparity in 404 breadth and potency between these two mAbs.

405

406 In addition to their distinct epitope-paratope interactions, the angle of approach is 407 likely different between the two mAbs. CAB-A17 makes interactions with the N417 408 residue through the Y33 residue on the heavy chain (28). mAb 084-7D possesses an 409 alanine at that position (A33) that would likely be unable to make strong contacts 410 with the asparagine at 417 due to its shorter side chain. Therefore, it is plausible that 411 mAb 084-7D interacts with the N417 residue using an alternative contact site(s) or 412 binds through a different angle of approach. It is important to note that the evolution 413 of the CAB-A17 mAb took place over seven months while 084-7D was isolated from 414 acute infection. Tracking the evolution of mAb 084-7D will reveal whether somatic 415 hypermutation led to increased potency and breadth and whether this maturation 416 mimicked the pathway used by CAB-A17 or followed an independent route.

417

418 The identification of another novel N417-dependent mAb that can neutralize various 419 VOC/VOIs indicates that this may be a good target for a cross-reactive response. 420 The CAB-A17 mAb was isolated earlier in the pandemic, presumably as a result of 421 D614G infection, while the 084-7D mAb was isolated from Beta infection, again 422 highlighting the universal targeting of this epitope by different variants. Despite the 423 divergence of variants into "serotypes" or "clusters", we show that the antibody 424 response towards different variants can converge on shared epitopes. Finding mAbs 425 that target conserved sites across variants will likely aid in the development of 426 therapeutic mAb cocktails that can treat SARS-CoV-2 infection regardless of the 427 infecting variant.

#### 430 Materials and Methods

431

#### 432 Cohort description

433 Plasma samples from the first SARS-CoV-2 wave (D614G-infected) were obtained 434 from a previously described cohort across various sites in South Africa prior to 435 September 2020 (3). Second wave samples (Beta-infected) were obtained from a 436 cohort of patients admitted to Groote Schuur Hospital, Cape Town in December 437 2020 - January 2021 (18). Third wave samples (Delta-infected) were obtained from 438 the Steve Biko Academic Hospital, Tshwane from patients admitted in July 2021. In 439 all waves, samples were collected when more than 90% of SARS-CoV-2 cases in 440 South Africa were caused by the respective variants. Sequence confirmation was 441 only available for a subset of samples but all the samples that were sequenced 442 corresponded to the appropriate variant for that wave. All samples were from HIV-443 uninfected individuals who were above 18 years of age and provided consent. 444 Ethical clearance was obtained for each cohort from Human Research Ethics 445 Committees from the University of Pretoria (247/2020) and University of Cape Town 446 (R021/2020).

447

#### 448 SARS-CoV-2 antigen design and expression

449 The pseudovirus SARS-CoV-2 Wuhan-1 spike was mutated using the QuikChange 450 Lightning Site-Directed Mutagenesis kit (Agilent Technologies) and NEBuilder HiFi 451 DNA Assembly Master Mix (NEB) into the 614G WT (D614G wild-type), Beta (L18F, 452 D80A, D215G, 242-244del, K417N, E484K, N501Y, D614G and A701V), Delta 453 (T19R, 156-157del, R158G, L452R, T478K, D614G, P681R and D950N), Delta plus 454 (Delta+) (T19R, 156-157del, R158G, K417N, L452R, T478K, D614G, P681R and 455 D950N), Gamma (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, 456 D614G, H655Y, T1027I, V1176F) and Omicron (A67V, Δ69-70, T95I, G142D, Δ143-457 145, Δ211, L212I, 214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, 458 S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, 459 H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F). The 460 SARS-CoV-1 spike was obtained from Genscript. Pseudoviruses were prepared as 461 previously described (3). Briefly, human embryonic kidney (HEK) 293T cells were co-

transfected with the SARS-CoV-2 spike plasmid of interest together with a firefly
luciferase encoding lentivirus backbone plasmid for 72 hours. Culture supernatants
were filter-sterilized and stored at -70°C.

For soluble proteins, the SARS-CoV-2 D614G spike was obtained from Jason 465 466 McLellan (University of Texas) and the SARS-CoV-2 RBD WT from Florian 467 Krammer. The full spike proteins were mutated to produce the 614G WT (D614G) 468 and Beta (L18F, D80A, D215G, 242-244del, K417N, E484K, N501Y, D614G and A701V), Delta (T19R, 156-157del, R158G, L452R, T478K, D614G, P681R and 469 470 D950N, A.VOI.V2 (D80Y, DEL144, I210N, DELN211, D215G, R246M, DEL LAL247-471 249,W258L, R346K, T478R, E484K, H655Y, P681H, Q957H) and Omicron (BA.1) 472 (A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, 214EPE, G339D, S371L, 473 S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, 474 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, 475 N856K, Q954H, N969K, L981F) spike proteins. SARS-CoV-2 subdomain 1 (SBD) 476 protein (residues: 321-591) and N-terminal domain (NTD) protein (residues: 14-304) 477 were designed in-house, ordered from Genscript and cloned into a mammalian cell 478 expression vector. Mutagenesis was used to produce SBD Beta (K417N, E484K or 479 N501Y) SBD K417N, SBD E484K, SBD N501Y single mutants and NTD Beta (L18F, 480 D80A, D215G, 242-244 del). Proteins were expressed in human embryonic kidney 481 HEK293F cells for 6 days, at 37°C, 70% humidity and 10% CO<sub>2</sub>. Purification was 482 carried out using a nickel-charged resin followed by size-exclusion chromatography. 483 Pure protein fractions were collected and frozen at -80°C until further use.

484

#### 485 SARS-CoV-2 monoclonal antibody isolation

Cryopreserved PBMCs from a SARS-CoV-2-infected participant, SA-01-0084, were stained for SARS-CoV-2-specific B-cell markers before single cell sorting. B-cells marked as CD3-, CD14-, CD16-, CD19+ and Aqua Vital Dye-negative were selected. Biotinylated SARS-CoV-2 Beta and D614G spike antigens were labelled with PE and AF647, respectively, through the biotin-streptavidin interaction. Viable cells that bound the Beta and/or D614G spikes were single-cell sorted into 96 well plates and heavy and light chain genes were PCR amplified.

#### 494 Single cell PCR amplification of heavy and light chain variable genes

Genes encoding IGHV and IGLV chains were amplified from sorted cells by reverse real-time and nested PCR. Reverse transcription was performed using Superscript III reverse transcriptase (Invitrogen) and random hexamer primers (36, 37). Following cDNA synthesis VH, V $\kappa$ , and V $\lambda$  antibody genes were amplified as previously described (38, 39). Determination of gene usage was done using IMGT/V-QUEST (https://www.imgt.org/IMGT\_vquest/analysis).

501

#### 502 Pseudovirus-based neutralization assay

Heat-inactivated plasma samples from COVID-19 convalescent donors or mAbs were incubated with the SARS-CoV-2 pseudoviruses for 1 hour at 37°C, 5% CO2. Subsequently,  $1x10^4$  HEK 293T cells engineered to over-express ACE-2, provided by Michael Farzan, were added and incubated at 37°C, 5% CO2 for 72 hours upon which the luminescence of the luciferase gene was measured. Monoclonal antibodies CB6, CA1 and CR3022 were used as controls.

509

#### 510 SARS-CoV-2 enzyme linked immunosorbent assay (ELISA)

511 96-well high-binding plates with 2 µg/ml of the respective antigen were incubated 512 overnight at 4°C. After blocking with 5% milk powder in 1x PBS and 0.05% Tween-513 20, mAbs at 5 µg/ml starting concentration was serially diluted and incubated at 514 room temperature for 1.5 hours. Subsequent washing was followed by the addition of 515 an anti-human horseradish peroxidase secondary antibody diluted to 1:3000 and the 516 plates were incubated for a further 1 hour. TMB substrate (ThermoFisher Scientific) 517 was added, followed by 1M  $H_2SO_4$  to stop the reaction, with absorbance of the 518 reaction measured at an optical density of 450nm. mAbs CR3022, P2B-2FB and 519 Palivizumab served as controls.

520

#### 521 Antibody-dependent cellular cytotoxicity (ADCC) assay

522 The ability of the mAb to cross-link between FcyRIIIa (CD16) and spike expressed 523 on cells was used as a proxy for ADCC. To express cell-surface spike, HEK 293T 524 cells were transfected with SARS-CoV-2 614G WT, Beta or Omicron expressing 525 plasmids, with incubation at 37°C over 2 days. Spike expressing cells were 526 incubated with 100 µg/ml of 084-7D or control mAbs titrated four times 1 in 5 in 527 RPMI media, 10% FBS, 1% penicillin-streptomycin for an hour at 37°C. Following 528 this, Jurkat-Lucia<sup>™</sup> NFAT-CD16 cells (Invitrogen) were added to the reaction, and incubated for a further 24 hours at 37°C with 10% CO<sub>2</sub>. Signal was read on a 529 530 luminometer by adding 20µl of supernatant and 50µl QUANTI-Luc secreted 531 luciferase to white 96-well plates. CR3022, P2B-2F6 and Palivizumab served as 532 controls and data across spikes were normalized using CR3022.

533

#### 534 Antibody-dependent cellular phagocytosis (ADCP) assay

535 Biotinylated SARS-CoV-2 614G WT, Beta and Omicron spike proteins were coated 536 onto beads by incubating fluorescent neutravidin beads with 10 µg/ml antibody for 2 537 hours as described elsewhere (22). Overnight incubation was carried out with 538 monocytic THP-1 cells, followed by analysis on the FACSAria II (BD Biosciences). 539 The percentage of engulfed fluorescent beads within the THP-1 cells multiplied by 540 the geometric mean was calculated and a final phagocytosis score was determined 541 by subtracting the fluorescence score of the no antibody control. CR3022, P2B-2F6 542 and Palivizumab served as controls.

543

544

#### 546 Conflicts of Interest

- 547
- 548 All authors declare no conflicts of interest.

549

#### 550 Acknowledgements

551

552 We acknowledge the participants who volunteered for this study. The parental 553 soluble SARS-CoV-2 spike was provided by J McLellan (University of Texas), 554 parental pseudovirus plasmids by Drs E Landais and D Sok (IAVI) and HEK 293T-555 ACE-2 cells were provided by Dr Michael Farzan (Scripps Research).

556

#### 557 Funders

558

PLM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa. This research was supported by the SA Medical Research Council SHIP program and the Bill and Melinda Gates Foundation, through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program.

#### 565 Figure legends

566

567 Figure 1: Comparison of plasma cross-reactivity elicited by three distinct 568 SARS-CoV-2 variants. (A) Plasma from D614G, Beta and Delta infections during 569 three distinct SARS-CoV-2 waves were tested for neutralization breadth against a 570 range of VOCs using a pseudovirus-based neutralization assay. Fold changes in 571 neutralization are shown above each variant. Plasma neutralization titer is measured 572 as an ID<sub>50</sub>. Black horizontal bars represent geometric means. The threshold of 573 detection for the neutralization assay is ID<sub>50</sub>>20. (**B**) Spider plots were derived from 574 GMTs for plasma triggered by D614G, Beta or Delta against multiple VOCs. The 575 GMTs for each plasma set was normalized against titers to the autologous virus and 576 breadth was expressed as area under the curve. (C) Plasma from Beta-infected 577 individuals was tested against the Delta and Delta+ variants. Fold changes in 578 neutralization are shown above each variant. Plasma neutralization titer is measured 579 as an ID<sub>50</sub>. Black horizontal bars represent geometric means. The threshold of 580 detection for the neutralization assay is  $ID_{50}>20$ .

581

582 Figure 2: Characterization of plasma and an isolated monoclonal antibody 583 from a Beta-infected individual. (A) A sequence-confirmed Beta-infected 584 hospitalized individual, SA-01-0084 (084) was selected for this study. Plasma and 585 peripheral blood mononuclear cells were collected 2 days post-positive PCR for 586 further analysis. (B) Plasma from SA-01-0084 was tested for neutralization activity in 587 a pseudovirus-based neutralization assay against a range of VOC/VOIs. Plasma 588 neutralization titer is measured as an  $ID_{50}$ . The threshold of detection for the 589 neutralization assay is  $ID_{50}$ >20. (C) The gating strategy for the isolation of SARS-590 CoV-2 spike-specific B cells via single cell sorting is shown. Each dot represents a 591 cell and the dots in the sorted cell red gate represent Beta spike-positive B cells that 592 had CD3-, CD14-, CD16-, CD19+ markers. These cells were single cell sorted into 593 96 well plates and amplified through antibody gene specific PCR. (D) mAb 084-7D 594 was tested for neutralization activity in a pseudovirus-based neutralization assay 595 against the same VOC/VOIs tested with the plasma. mAb neutralization was 596 measured as an  $IC_{50}$  (ug/ml). The threshold of detection for the neutralization assay 597 is  $IC_{50}>20$  ug/ml (E) A SARS-CoV-2 ELISA was used to map the specificity of the 598 084-7D mAb. The mAb was tested against the D614G and Beta N-terminal domain,

spike and RBD antigens, as well as SBD (subdomain 1) proteins mutated to include
Beta-specific SBD single mutants, K417N, E484K and N501Y. The starting
concentration of the mAb was 5ug/ml. The threshold of detection for the binding
assay is OD450nm>0.04.

603

604 Figure 3: mAb 084-7D displayed antibody dependent cellular phagocytosis 605 (ADCP) and antibody dependent cellular cytotoxicity (ADCC) with cross 606 reactivity towards Beta and Omicron. (A) ADCP activity of mAb 084-7D was 607 measured using THP-1 phagocytosis assay and the phagocytosis score shown as 608 an area under the curve (AUC) measure. The threshold of detection for this assay is 609 AUC>0. (B) ADCC activity of mAB 094-7D was measured using an infectious ADCC 610 assay. The % killing activity is shown as an AUC measure. The threshold of 611 detection for the ADCC assay is AUC>8000. In both ADCP and ADCC assays P2B-612 2F6 was used a positive control for D614G activity, CR3022 was used as a positive 613 control for all variants and Palivizumab, an RSV-specific mAb, was used as a 614 negative control. Experiments were conducted in duplicate and error bars represent 615 the mean with standard deviation of two experiments.

616

617 Figure 4: Genetic analysis of mAb 084-7D compared to a similar N417-618 dependent mAb. (A) Heavy chain and (B) light chain analysis of mAb 087-7D was conducted using IMGT/V-QUEST (https://www.imgt.org/IMGT\_vquest/analysis). A 619 620 multiple sequence alignment of the germline gene and mAb sequences for 084-7D 621 and CAB-A17 was generated using ClustalW (https://www.genome.jp/tools-622 bin/clustalw). Key positions implicated in the development of breadth in the CAB-A17 623 mAb are shown in bold and mutations from germline gene residues in these regions 624 are shown in red.

625

#### 627 **References**

- Hirabara SM, Serdan TD, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, Curi
   R, Durigon EL. 2022. SARS-COV-2 Variants: Differences and Potential of
   Immune Evasion. Frontiers in Cellular and Infection Microbiology:1401.
- Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J,
  Doolabh D, Pillay S, San EJ, Msomi N. 2021. Detection of a SARS-CoV-2
  variant of concern in South Africa. Nature 592:438-443.
- Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen
  B, Lambson BE, De Oliveira T, Vermeulen M, Van der Berg K. 2021. SARSCoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor
  plasma. Nature medicine 27:622-625.
- 639 4. Scheepers C, Everatt J, Amoako DG, Tegally H, Wibmer CK, Mnguni A, 640 Ismail A, Mahlangu B, Lambson BE, Richardson SI, Martin DP, Wilkinson E, San JE, Giandhari J, Manamela N, Ntuli N, Kgagudi P, Cele S, Pillay S, 641 Mohale T, Ramphal U, Naidoo Y, Khumalo ZT, Kwatra G, Gray G, Bekker L-642 G, Madhi SA, Baillie V, Van Voorhis WC, NGS-SA, Treurnicht FK, Venter M, 643 Mlisana K, Wolter N, Sigal A, Williamson C, Hsiao N-y, Msomi N, Maponga T, 644 Preiser W, Makatini Z, Lessells R, Moore PL, de Oliveira T, von Gottberg A, 645 Bhiman JN. 2021. Emergence and phenotypic characterization of C.1.2, a 646 647 globally detected lineage that rapidly accumulated mutations of concern. 648 medRxiv doi:10.1101/2021.08.20.21262342:2021.08.20.21262342.
- 649 5. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji 650 UJ, Bester PA, Boni MF, Chand M, Choga WT, Colguhoun R, Davids M, 651 Deforche K, Doolabh D, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M, Hardie D, Hill V, Hsiao N-Y, Iranzadeh A, Ismail A, Joseph C, Joseph R, 652 Koopile L, Pond SLK, Kraemer MU, Kuate-Lere L, Laguda-Akingba O, 653 Lesetedi-Mafoko O, Lessells RJ, Lockman S, Lucaci AG, Maharaj A, 654 Mahlangu B, Maponga T, Mahlakwane K, Makatini Z, Marais G, Maruapula D, 655 Masupu K, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Mendes A, 656 Mlisana K, Mnguni A, et al. 2021. Rapid epidemic expansion of the SARS-657 658 CoV-2 Omicron variant Africa. medRxiv in southern doi:10.1101/2021.12.19.21268028:2021.12.19.21268028. 659
- 6. de Oliveira T, Lutucuta S, Nkengasong J, Morais J, Paixão JP, Neto Z, Afonso
  P, Miranda J, David K, Inglês L, Raisa Rivas Carralero APAP, Freitas HR,
  Mufinda F, Tessema SK, Tegally H, San EJ, Wilkinson E, Giandhari J, Pillay
  S, Giovanetti M, Naidoo Y, Katzourakis A, Ghafari M, Singh L, Tshiabuila D,
  Martin D, Lessells RJ. 2021. A novel variant of interest of SARS-CoV-2 with
  multiple spike mutations detected through travel surveillance in Africa.
  medRxiv doi:10.1101/2021.03.30.21254323:2021.03.30.21254323.
- Sheward DJ, Kim C, Ehling RA, Pankow A, Dopico XC, Martin D, Reddy S,
  Dillner J, Karlsson Hedestam GB, Albert J, Murrell B. 2021. Variable loss of
  antibody potency against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv
  doi:10.1101/2021.12.19.473354:2021.12.19.473354.
- 8. Cele S, Jackson L, Khan K, Khoury D, Moyo-Gwete T, Tegally H, Scheepers
   C, Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y,
   Jule Z, Reedoy K, San JE, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI,
   Karim SA, Hanekom W, NGS-SA, Team C-K, von Gottberg A, Bhiman J,
   Lessells RJ, Moosa M-YS, Davenport M, de Oliveira T, Moore PL, Sigal A.

- 676 2021. Omicron extensively but incompletely escapes Pfizer BNT162b2 677 neutralization. Nature doi:10.1038/d41586-021-03824-5.
- 678 9. Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitido AD, Sheehan
  679 ML, Berrios C, Ofoman O, Chang CC, Hauser BM. 2022. mRNA-based
  680 COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV681 2 Omicron variant. Cell.
- Laurini E, Marson D, Aulic S, Fermeglia A, Pricl S. 2021. Molecular rationale
   for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and
   etesevimab monoclonal antibodies. Scientific Reports 11:20274.
- Arora P, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Winkler MS, Schulz
  S, Jäck H-M, Stankov MV, Behrens G. 2021. Delta variant (B. 1.617. 2)
  sublineages do not show increased neutralization resistance. Cellular &
  molecular immunology 18:2557-2559.
- Kumar S, Karuppanan K, Subramaniam G. 2022. Omicron (BA.1) and SubVariants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and
  Pathogenicity: A Comparative Sequence and Structural-based Computational
  Assessment. bioRxiv doi:10.1101/2022.02.11.480029:2022.02.11.480029.
- Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB,
  Malyutin AG, Sharaf NG, Huey-Tubman KE, Lee YE. 2020. SARS-CoV-2
  neutralizing antibody structures inform therapeutic strategies. Nature:1-6.
- Greaney AJ, Starr TN, Eguia RT, Loes AN, Khan K, Karim F, Cele S, Bowen JE, Logue JK, Corti D. 2022. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS pathogens 18:e1010248.
- Greaney AJ, Eguia RT, Starr TN, Khan K, Franko N, Logue JK, Lord SM,
  Speake C, Chu HY, Sigal A, Bloom JD. 2022. The SARS-CoV-2 Delta variant
  induces an antibody response largely focused on class 1 and 2 antibody
  epitopes. bioRxiv doi:10.1101/2022.03.12.484088:2022.03.12.484088.
- 704 16. Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, 705 Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino 706 B, Minola A, Zatta F, Sprugasci N, Bassi J, Peter A, De Marco A, Nix JC, Mele F, Jovic S, Rodriguez BF, Gupta SV, Jin F, Piumatti G, Lo Presti G, Pellanda 707 708 AF, Biggiogero M, Tarkowski M, Pizzuto MS, Cameroni E, Havenar-Daughton 709 C, Smithey M, Hong D, Lepori V, Albanese E, Ceschi A, Bernasconi E, Elzi L, 710 Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink K, Virgin HW, Lanzavecchia A, Corti D, Veesler D. 2020. Mapping Neutralizing and 711 712 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain 713 by Structure-Guided High-Resolution Serology. Cell 183:1024-1042.e21.
- 714 17. Greaney AJ, Loes AN, Gentles LE, Crawford KH, Starr TN, Malone KD, Chu
  715 HY, Bloom JD. 2021. Antibodies elicited by mRNA-1273 vaccination bind
  716 more broadly to the receptor binding domain than do those from SARS-CoV-2
  717 infection. Science translational medicine 13:eabi9915.
- 18. Moyo-Gwete T, Madzivhandila M, Makhado Z, Ayres F, Mhlanga D,
  Oosthuysen B, Lambson BE, Kgagudi P, Tegally H, Iranzadeh A, Doolabh D,
  Tyers L, Chinhoyi LR, Mennen M, Skelem S, Marais G, Wibmer CK, Bhiman
  JN, Ueckermann V, Rossouw T, Boswell M, de Oliveira T, Williamson C,
  Burgers WA, Ntusi N, Morris L, Moore PL. 2021. Cross-Reactive Neutralizing
  Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). New
  England Journal of Medicine doi:10.1056/NEJMc2104192:2161-2163.

- 19. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, Snyman J, MoyoGwete T, Wilkinson E, Bernstein M. 2022. SARS-CoV-2 prolonged infection
  during advanced HIV disease evolves extensive immune escape. Cell host &
  microbe 30:154-162. e5.
- Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai
  R, Zhou D, Mentzer AJ, Zhao Y. 2021. Reduced neutralization of SARS-CoV2 B. 1.617 by vaccine and convalescent serum. Cell 184:1-17.
- 21. Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, 732 733 Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettner I, 734 Jimenez-Guardeño JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao 735 RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead 736 C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim 737 MH, Doores KJ. 2021. Neutralizing antibody activity in convalescent sera from 738 infection in humans with SARS-CoV-2 and variants of concern. Nature 739 Microbiology 6:1433-1442.
- Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht
  MA, Lambson BE, Oosthuysen B, Ayres F, Makhado Z, Moyo-Gwete T. 2022.
  SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector
  functions in previously vaccinated, but not unvaccinated individuals. Cell Host
  & Microbe.
- Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V,
  Marot S, Jary A, Todesco E, Schnuriger A. 2021. The Delta SARS-CoV-2
  variant has a higher viral load than the Beta and the historical variants in
  nasopharyngeal samples from newly diagnosed COVID-19 patients. Journal
  of Infection 83:e1-e3.
- 750 24. Wilks SH, Mühlemann B, Shen X, Türeli S, LeGresley EB, Netzl A, Caniza MA, Chacaltana-Huarcaya JN, Daniell X, Datto MB, Denny TN, Drosten C, 751 Fouchier RAM, Garcia PJ, Halfmann PJ, Jassem A, Jones TC, Kawaoka Y, 752 Krammer F, McDanal C, Pajon R, Simon V, Stockwell M, Tang H, van Bakel 753 H, Webby R, Montefiori DC, Smith DJ. 2022. Mapping SARS-CoV-2 antigenic 754 755 relationships serological and responses. bioRxiv 756 doi:10.1101/2022.01.28.477987:2022.01.28.477987.
- Reincke SM, Yuan M, Kornau H-C, Corman VM, van Hoof S, Sánchez-Sendin
  E, Ramberger M, Yu W, Hua Y, Tien H. 2022. SARS-CoV-2 Beta variant
  infection elicits potent lineage-specific and cross-reactive antibodies. Science
  375:782-787.
- Richardson SI, Manamela NP, Motsoeneng BM, Kaldine H, Ayres F, Makhado
  Z, Mennen M, Skelem S, Williams N, Sullivan NJ. 2022. SARS-CoV-2 Beta
  and Delta variants trigger Fc effector function with increased cross-reactivity.
  Cell Reports Medicine:100510.
- Zohar T, Loos C, Fischinger S, Atyeo C, Wang C, Slein MD, Burke J, Yu J,
  Feldman J, Hauser BM. 2020. Compromised humoral functional evolution
  tracks with SARS-CoV-2 mortality. Cell 183:1508-1519. e12.
- Sheward DJ, Pushparaj P, Das H, Kim C, Kim S, Hanke L, Dyrdak R,
  McInerney GM, Albert J, Murrell B. 2022. Structural basis of Omicron neutralization by affinity-matured public antibodies. bioRxiv.
- Yuan M, Liu H, Wu NC, Lee C-CD, Zhu X, Zhao F, Huang D, Yu W, Hua Y,
  Tien H, Rogers TF, Landais E, Sok D, Jardine JG, Burton DR, Wilson IA.
  2020. Structural basis of a shared antibody response to SARS-CoV-2.
  Science 369:1119-1123.

- Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S,
  Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu
  L, Zhao J, Wang X, Zhang Z, Zhang L. 2020. Human neutralizing antibodies
  elicited by SARS-CoV-2 infection. Nature 584:115-119.
- Xu H, Wang B, Zhao T-N, Liang Z-T, Peng T-B, Song X-H, Wu J-J, Wang YC, Su X-D. 2021. Structure-based analyses of neutralization antibodies
  interacting with naturally occurring SARS-CoV-2 RBD variants. Cell Research
  31:1126-1129.
- 32. Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng
  C. 2020. Potent neutralizing antibodies against SARS-CoV-2 identified by
  high-throughput single-cell sequencing of convalescent patients' B cells. Cell
  182:73-84. e16.
- Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D,
  Wang Z, Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE. 2021. Affinity
  maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth,
  and resilience to viral escape mutations. Immunity 54:1853-1868. e7.
- 34. Derdeyn CA, Moore PL, Morris L. 2014. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9:210-6.
- Klein F, Diskin R, Scheid Johannes F, Gaebler C, Mouquet H, Georgiev IS,
  Pancera M, Zhou T, Incesu R-B, Fu Brooks Z, Gnanapragasam Priyanthi NP,
  Oliveira Thiago Y, Seaman Michael S, Kwong Peter D, Bjorkman Pamela J,
  Nussenzweig Michel C. 2013. Somatic Mutations of the Immunoglobulin
  Framework Are Generally Required for Broad and Potent HIV-1
  Neutralization. Cell 153:126-138.
- Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H.
  2008. Efficient generation of monoclonal antibodies from single human B cells
  by single cell RT-PCR and expression vector cloning. J Immunol Methods
  329:112-24.
- Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch
  J, Fenyo D, Abadir A, Velinzon K. 2011. Sequence and structural
  convergence of broad and potent HIV antibodies that mimic CD4 binding.
  Science 333:1633-1637.
- Boria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY,
  Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz
  A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S,
  Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, Haynes
  BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR.
  2015. New Member of the V1V2-Directed CAP256-VRC26 Lineage That
  Shows Increased Breadth and Exceptional Potency. J Virol 90:76-91.
- 815 39. Liao H-X, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, Parks R,
  816 Whitesides J, Marshall DJ, Hwang K-K. 2009. High-throughput isolation of
  817 immunoglobulin genes from single human B cells and expression as
  818 monoclonal antibodies. Journal of virological methods 158:171-179.
- 819



Sample ID	SA-01-0084
Sex	Female
Age	55-60
HIV status	Uninfected
Days post-positive RT-PCR test	2 days
Date blood sample colelcted	January 2021
Beta infection sequence confimed	Yes

084 plasma

(KATTAN ONOO Delta

101.40V1

Ganne

mAb 084-7D

Deter that The Grad and Dive of

Α

Β

D

100,000

10,000

1,000

100

10

0.001 -

0.01 0.1

1

10

100

15MS

Neutralization titer (IC<sub>50</sub>)

TONE

Beta

Delta\*

Neutralization titer (ID<sub>50</sub>)



medRxiv preprint doi: https://doi.org/10.1101/2022.04.24.22273395; this version posted April 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



### Figure 3

#### mAb 084-7D heavy chain

Α

В

			Gene usage					
mAbID	Isolated as	Cloned as	νн	D	J	V-gene Mutation frequency	CDRH3 length	CDRH3 AA Sequence
084-7D	IgG1, IgA1, IgM	lgG1	3-23*01	2-8*01	1*01	5,9%	13	AKDHPSWGSSFLN

	1	20	) 4(		
VH3-23*01	EVQLLESGGG	LVQPGGSLRL	SCAAS $\mathbf{G}$ F $\mathbf{T}$ FS	SYAMSWVRQA	PGKGLEWVSA
VH3-53*01	EVQLVESGGG	LIQPGGSLRL	SCAAS $\mathbf{G}\mathbf{F}\mathbf{T}\mathbf{V}\mathbf{S}$	SNYMSWVRQA	PGKGLEWVSV
CAB-A17-HC	DVHLVESGG-	LIQPGGSLRL	SCAASEFIVS	ANYMSWVRQA	PGEGLQWVSV
084-7D HC	EVQLLESGGG	LVQPGGSLRL	SCAAS <b>G</b> F <mark>S</mark> FS	SYAMNWVRQA	PGKGLEWVSA

	60	)	80		
VH3-23*01	ISGSGGSTYY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAK
VH3-53*01	IY- <b>S</b> GGST <b>Y</b> Y	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAR
CAB-A17-HC	IY-PGGSTFY	AESVKGRFTI	SRDNSRNTLY	LQMNSLRAED	TGVYYCAR
084-7D HC	ISG <b>G</b> GDNI <b>Y</b> Y	ADSVKGRFTI	SRDNYKNTLH	LOMKSLRAED	TAVYYCAK

### mAb 084-7D light chain

	Gene	usage			
mAb ID	VK	J	V-gene Mutation frequency	CDRL3 length	CDRL3 AA Sequence
084-7D	1-5*03	4*01	2,9%	9	QQYNSYSLT

	1	20	40		
VK1-5*03	DIQMTQSPST	LSASVGDRVT	ITCRASQS I-	<b>SS</b> WLAWYQQK	PGKAPKLLIY
VK3-20*01	EIVLTQSPGT	LSLSPGERAT	LSCRASQS ${f vs}$	<b>SS</b> YLAWYQQK	PGQAPRLLIY
CAB-A17-LC	EIVLTQSPGT	LSLSPGERAS	LSCRASQS <mark>LS</mark>	- <b>T</b> YLAWYQQK	PGQAPRLLIF
084-7D LC	DIQMTQSPST	LSASVGDRVT	ITCRASQS <mark>I</mark> -	<mark>SS</mark> WLAWYQQK	PGRAPKLLIY
	60		80		
VK1-5*03	KASSLESGVP	SRFSGSGSGT	EFTLTISSLQ	PDDFATYYCQ	QYNSYS
VK3-20*01	GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QYGSSP
CAB-A17-LC	GASSRASGIP	DRFSGGGSGT	DFTLTISRLE	PEDFAVYYCQ	QYGSSP
084-7D LC	TASNLESGVP	SRFSGSGSGT	EFSLTISSLQ	PDDFATYYCQ	QYNSYS

Figure 4